Endo Pharmaceuticals Inc. February 19, 2008
Exhibit 10.48.6
| Endo Pharmaceuticals Inc. | February 19, 2008 |
000 Xxxxxxxx Xxxxx
Xxxxxx Xxxx XX 00000
Attn: Chief Legal Officer
| Copy: | Skadden, Arps, Slate, Xxxxxxx & Xxxx LLP Xxxx Xxxxx Xxxxxx Xxx Xxxx XX 00000 Attn: Xxxxxx Xxxxxx and Xxxxx Xxxxxxx |
Dear Sirs,
We refer to our co-promotion agreement dated 1st July 2005 relating to the co-promotion of frovatriptan in the U.S.A (the “Co-Promotion Agreement”).
Pursuant to Clause 9.3 of the Co-Promotion Agreement we hereby agree to cease our co-promotion of frovatriptan in the U.S.A. and to terminate the Co-Promotion Agreement with effect from February 19, 2008.
Please confirm your agreement to this termination and its effective date by countersigning a copy of this letter and returning it to us.
Yours faithfully,
for and on behalf of Vernalis Development Ltd.
| /s/ X. X. Xxxx |
||
| Director | ||
| Agreed for and on behalf of Endo Pharmaceuticals Inc. | ||
| /s/ Xxxxxxx X. Xxxxxxx |
||
| EVP, CFO & Treasurer | (title) | |
| 2-19-08 | (date) | |
